Dicloxacillin Sodium
FDA-approved product (capsule, oral), marketed as Dicloxacillin Sodium, Dycill, Dynapen and 1 more.
- Registered studies
- 17
- Lab records
- 0
- Pathogens at ≥40%
- 2 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Bacterial disease
- Infection
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Beta-lactamase resistant penicillins
- Anti-infective classification
- Classified as an existing antimicrobial.WHO ATC J01CF01
Repurposing investigation
Dicloxacillin Sodium is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.
AI-predicted activity
AI prediction · nothing measured- MRSA24.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- E. coli26.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- K. pneumoniae50.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- M. tuberculosis41.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
17registered studies name this medicine, for any condition. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredAutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Dicloxacillin Sodium with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- Galantamine HydrobromideExisting use: Alzheimer disease, Dementia89.6% AI-predicted activityagainst K. pneumoniaeLab records exist50+ registered studies
- Chlorhexidine GluconateExisting use: Eye infection, Gingivitis, Infection and 2 more69.3% AI-predicted activityagainst K. pneumoniaeLab records exist50+ registered studies
- TriclosanExisting use: Phenol and derivatives, Medicated dressings with antiinfectives68.0% AI-predicted activityagainst K. pneumoniaeLab records exist50+ registered studies
- ElvitegravirExisting use: HIV infection, HIV-1 infection, Viral disease60.2% AI-predicted activityagainst K. pneumoniae50+ registered studies
- Caspofungin AcetateExisting use: Aspergillosis, Candidemia, Candidiasis and 1 more57.5% AI-predicted activityagainst K. pneumoniae50+ registered studies
- DactinomycinExisting use: Kidney Wilms tumor, Neoplasm56.8% AI-predicted activityagainst K. pneumoniae50+ registered studies
- CyclosporineExisting use: Conjunctivitis, Corneal disease, Eye disease and 6 more56.1% AI-predicted activityagainst K. pneumoniae50+ registered studies
- LinaclotideExisting use: Constipation, Constipation disorder, Irritable bowel syndrome56.0% AI-predicted activityagainst K. pneumoniae50+ registered studies
- Irinotecan HydrochlorideExisting use: Adenocarcinoma, Cancer, Carcinoma and 4 more54.5% AI-predicted activityagainst K. pneumoniae50+ registered studies
- OxytocinExisting use: Hemorrhage, Uterine Inertia52.7% AI-predicted activityagainst K. pneumoniae50+ registered studies
- Micafungin SodiumExisting use: Candidiasis52.4% AI-predicted activityagainst K. pneumoniae50+ registered studies
- VoclosporinExisting use: Immune system disease, Lupus nephritis52.2% AI-predicted activityagainst K. pneumoniae28 registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
Antibiotic Treatment for Infections of Short Term In-dwelling Vascular Catheters Due to Gram Positive Bacteria
NCT00037050 · start 2002-04
Registered record
- Registry ID
- NCT00037050
- Conditions
- Bacterial Infections; Gram-Positive Bacterial Infections; Bacteremia
- Interventions
- Linezolid; Vancomycin; Oxacillin; Dicloxacillin
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2002-04
- Completion
- 2005-07
- Enrolment
- 739
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionBacterial Infections; Gram-Positive Bacterial Infections; BacteremiaInterventionLinezolid; Vancomycin; Oxacillin; DicloxacillinPhasePhase 3Registry statusCompletedCefazolin Versus Antistaphylococcal Penicillins for Methicillin Susceptible Staphylococcus Aureus Bacteremia
NCT07186894 · start 2000-01-01
Registered record
- Registry ID
- NCT07186894
- Conditions
- Bacteriemia; Methicillin Susceptible Staphylococcus Aureus (MSSA) Infection
- Interventions
- Antistaphylococcal penicillins; Cefazolin
- Study type
- OBSERVATIONAL
- Phase
- Not recorded
- Registry status
- Active not recruiting
- Start
- 2000-01-01
- Completion
- 2026-09-01
- Enrolment
- 5,000
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionBacteriemia; Methicillin Susceptible Staphylococcus Aureus (MSSA) InfectionInterventionAntistaphylococcal penicillins; CefazolinPhaseNot recordedRegistry statusActive not recruiting